Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr Miele Cosmed GroupFRA:9PU -2.34%70 Debt-to-EBITDA is 1.71 as of Mar. 2026, which is 5% below its 10-year median of 1.80. GuruFocus rates FRA:9PU with a GF Score™ of 70/100 and a GF Value™ of €0.86. The stock has 2 warning signs investors should review. Among 1,563 Consumer Packaged Goods companies, Dr Miele Cosmed Group ranks better than 56.75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dr Miele Cosmed Group's Debt-to-EBITDA or its related term are showing as below:
FRA:9PU'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.26 Med: 1.8 Max: 15.61
Current: 1.64
During the past 13 years, the highest Debt-to-EBITDA Ratio of Dr Miele Cosmed Group was 15.61. The lowest was -1.26. And the median was 1.80.
FRA:9PU's Debt-to-EBITDA is ranked better than 56.75% of 1563
companies
in the Consumer Packaged Goods industry
Industry Median: 2.13
vs FRA:9PU: 1.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dr Miele Cosmed Group Debt-to-EBITDA Related Terms
Dr Miele Cosmed Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Dr Miele Cosmed Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Dr Miele Cosmed Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Miele Cosmed Group Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dr Miele Cosmed Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dr Miele Cosmed Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Dr Miele Cosmed Group (FRA:9PU) has a Debt-to-EBITDA of 1.71 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Miele Cosmed Group. This is near median its historical median of 1.80. According to the industry distribution chart, Dr Miele Cosmed Group ranks #676 out of 1563 companies in the Consumer Packaged Goods industry, placing it in the top 43.3%.
Is Dr Miele Cosmed Group's Debt-to-EBITDA too high?
Dr Miele Cosmed Group's current Debt-to-EBITDA of 1.71 is near median its 10-year median of 1.80. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.13. Dr Miele Cosmed Group's value of 1.71 is 19.7% below this industry median. Based on the distribution chart, Dr Miele Cosmed Group ranks #676 out of 1563 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Dr Miele Cosmed Group has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Dr Miele Cosmed Group's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Dr Miele Cosmed Group ranks #676 out of 1563 companies for Debt-to-EBITDA. This puts Dr Miele Cosmed Group in the upper half of its industry. The industry median Debt-to-EBITDA is 2.13. Dr Miele Cosmed Group's value of 1.71 is 19.7% below this benchmark. While the company's 10-year median is 1.80 vs. the industry median of 2.13, Dr Miele Cosmed Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.13, based on 1,563 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr Miele Cosmed Group's current Debt-to-EBITDA of 1.71 is 19.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dr Miele Cosmed Group. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Miele Cosmed Group's current Debt-to-EBITDA is 1.71, which is near median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Miele Cosmed Group stock overvalued right now?
Dr Miele Cosmed Group (FRA:9PU) has a current Debt-to-EBITDA of 1.71. The stock's GF Value™ is €0.86, compared to a current price of €0.50 — trading 41.9% below its estimated fair value. The current Debt-to-EBITDA is 1.71, which is near median its 10-year median of 1.80 and 19.7% below the Consumer Packaged Goods industry median of 2.13. Dr Miele Cosmed Group's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dr Miele Cosmed Group (FRA:9PU), the current Debt-to-EBITDA is 1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Miele Cosmed Group (FRA:9PU) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Miele Cosmed Group stock appears to be undervalued.
The current stock price of €0.50 is trading 41.9% below its estimated GF Value™ of €0.86.
Key valuation signals for FRA:9PU:
Debt-to-EBITDA: 1.71 (near median its 10-year median of 1.80)
GF Value™: €0.86 vs. price of €0.50 (41.9% below fair value)
Industry Position: 19.7% below the Consumer Packaged Goods median (#676 of 1563)
No single metric tells the full story. See the FRA:9PU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr Miele Cosmed Group SA is engaged in manufacturing cosmetics and household chemicals for national and international retailers, fulfils consumer needs in the sector of personal care, hygiene and cleanliness. The company's brands include Apart, Biophen, Mole, Bobini, Sofin and Izo.
70GF Score
Get the complete analysis for FRA:9PU
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9PU has been successfully added to your 
